TWI546301B - 葡萄糖神經醯胺合成酶抑制劑 - Google Patents

葡萄糖神經醯胺合成酶抑制劑 Download PDF

Info

Publication number
TWI546301B
TWI546301B TW101109086A TW101109086A TWI546301B TW I546301 B TWI546301 B TW I546301B TW 101109086 A TW101109086 A TW 101109086A TW 101109086 A TW101109086 A TW 101109086A TW I546301 B TWI546301 B TW I546301B
Authority
TW
Taiwan
Prior art keywords
compound
group
formula
methyl
disease
Prior art date
Application number
TW101109086A
Other languages
English (en)
Chinese (zh)
Other versions
TW201300383A (zh
Inventor
伊利斯 波克
卡山卓拉 塞拉卡
布萊德佛 賀詩
馬庫斯 梅茲
趙忠
雷納多 斯克
項宜賓
凱薩琳 珍希西克斯
約翰 馬修
程森
羅納德 雪爾
馬立歐 卡貝拉薩拉札
安德魯 古德
Original Assignee
健臻公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 健臻公司 filed Critical 健臻公司
Publication of TW201300383A publication Critical patent/TW201300383A/zh
Application granted granted Critical
Publication of TWI546301B publication Critical patent/TWI546301B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
TW101109086A 2011-03-18 2012-03-16 葡萄糖神經醯胺合成酶抑制劑 TWI546301B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161454034P 2011-03-18 2011-03-18
US201261590711P 2012-01-25 2012-01-25

Publications (2)

Publication Number Publication Date
TW201300383A TW201300383A (zh) 2013-01-01
TWI546301B true TWI546301B (zh) 2016-08-21

Family

ID=46879977

Family Applications (2)

Application Number Title Priority Date Filing Date
TW105121161A TWI634119B (zh) 2011-03-18 2012-03-16 葡萄糖神經醯胺合成酶抑制劑
TW101109086A TWI546301B (zh) 2011-03-18 2012-03-16 葡萄糖神經醯胺合成酶抑制劑

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW105121161A TWI634119B (zh) 2011-03-18 2012-03-16 葡萄糖神經醯胺合成酶抑制劑

Country Status (38)

Country Link
US (5) US9139580B2 (enExample)
EP (3) EP4559918A3 (enExample)
JP (2) JP6117708B2 (enExample)
KR (1) KR101987736B1 (enExample)
CN (2) CN107080747B (enExample)
AR (1) AR085425A1 (enExample)
AU (2) AU2012231275A1 (enExample)
BR (2) BR122019017719B1 (enExample)
CA (1) CA2830540C (enExample)
CL (1) CL2013002688A1 (enExample)
CO (1) CO6801749A2 (enExample)
CR (1) CR20190034A (enExample)
DK (2) DK3673906T3 (enExample)
DO (1) DOP2013000209A (enExample)
EC (1) ECSP13012978A (enExample)
ES (2) ES2774293T3 (enExample)
FI (1) FI3673906T3 (enExample)
GT (1) GT201300215A (enExample)
HR (2) HRP20200226T1 (enExample)
HU (2) HUE047888T2 (enExample)
IL (1) IL228514B (enExample)
LT (2) LT3673906T (enExample)
MA (1) MA35023B1 (enExample)
MX (3) MX365245B (enExample)
MY (1) MY173998A (enExample)
NI (1) NI201300083A (enExample)
PE (1) PE20140412A1 (enExample)
PH (1) PH12013501944A1 (enExample)
PL (2) PL2685986T3 (enExample)
PT (2) PT3673906T (enExample)
RS (2) RS59963B1 (enExample)
RU (2) RU2018104472A (enExample)
SI (2) SI3673906T1 (enExample)
TW (2) TWI634119B (enExample)
UA (1) UA118248C2 (enExample)
UY (1) UY33958A (enExample)
WO (1) WO2012129084A2 (enExample)
ZA (1) ZA201307016B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI634119B (zh) * 2011-03-18 2018-09-01 美商健臻公司 葡萄糖神經醯胺合成酶抑制劑
TWI865485B (zh) * 2019-02-04 2024-12-11 美商健臻公司 用於治療溶體儲積症相關的症狀和病症之方法（一）

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20130273B1 (ar) * 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
AU2019222801B2 (en) * 2012-09-11 2021-02-18 Genzyme Corporation Glucosylceramide synthase inhibitors
JO3713B1 (ar) * 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
CN105189491B (zh) * 2013-03-15 2018-07-06 建新公司 制备葡萄糖基神经酰胺合酶抑制剂的方法
CN104418851A (zh) * 2013-09-02 2015-03-18 上海龙翔生物医药开发有限公司 奎宁环衍生物的制备方法及纯化方法
CN105979945A (zh) * 2013-12-11 2016-09-28 建新公司 葡糖神经酰胺合酶抑制剂
BR112016028081A2 (pt) * 2014-05-30 2017-08-22 Sphaera Pharma Private Ltd Novos compostos como agentes antituberculares
EP3253734B1 (en) 2015-02-02 2020-12-23 The Regents of The University of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
CN108290894A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的4-甲基-吡咯并[1,2-a]嘧啶-8-甲酰胺类化合物及其调节葡糖脑苷脂酶活性的用途
EP3317265A4 (en) * 2015-07-01 2019-04-17 Northwestern University SUBSTITUTED CHINAZOLIN COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
EP3433623A2 (en) 2016-03-25 2019-01-30 Genzyme Corporation Biomarkers of proteopathies and uses thereof
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
CA3043709A1 (en) 2016-11-14 2018-05-17 Berg Llc Methods for treating parkinson's disease
CN110494432B (zh) 2016-12-28 2022-08-12 米尼奥尔克斯治疗有限公司 异喹啉化合物，其制备方法及其在与β-半乳糖苷酶活性改变相关的病症中的治疗用途
CA3048357A1 (en) 2016-12-29 2018-07-05 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
CN108341822B (zh) * 2017-01-23 2021-04-16 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和应用
US11498904B2 (en) * 2017-11-14 2022-11-15 Merck Sharp & Dohme Llc Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
WO2019126776A1 (en) 2017-12-21 2019-06-27 Lysosomal Therapeutics Inc. Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
WO2019151269A1 (ja) * 2018-01-31 2019-08-08 武田薬品工業株式会社 複素環化合物
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
KR102342901B1 (ko) * 2018-11-22 2021-12-24 (주)프로스테믹스 엑소좀 및 이의 다양한 용도
KR102342902B1 (ko) * 2018-11-22 2021-12-24 (주)프로스테믹스 엑소좀 및 이의 다양한 용도
KR102233530B1 (ko) * 2018-11-22 2021-03-31 (주)프로스테믹스 엑소좀 및 이의 다양한 용도
WO2020163337A1 (en) 2019-02-04 2020-08-13 Genzyme Corporation Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs)
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
JP7539382B2 (ja) * 2019-07-29 2024-08-23 武田薬品工業株式会社 複素環化合物
JP7698320B2 (ja) 2019-10-23 2025-06-25 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミドシンターゼ阻害剤およびそれを使用する治療方法
WO2021096241A1 (en) * 2019-11-15 2021-05-20 Yuhan Corporation Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
MX2022005679A (es) * 2019-11-15 2022-06-27 Yuhan Corp Nuevos derivados que tienen una fraccion de 2,3-dihidro-1h-indeno o 2,3-dihidrobenzofurano o una sal farmaceuticamente aceptable de los mismos y composiciones farmaceuticas que los comprenden.
MX2022006059A (es) 2019-11-25 2022-09-12 Gain Therapeutics Sa Compuestos de arilo y heteroarilo, y usos terapeuticos de los mismos en condiciones asociadas con la alteracion de la actividad de galactocerebrosidasa.
WO2021105908A1 (en) 2019-11-25 2021-06-03 Gain Therapeutics Sa Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase
US20230140216A1 (en) 2020-02-03 2023-05-04 Gain Therapeutics Sa Combination therapy for treating mps1
BR112022014553A2 (pt) * 2020-02-03 2022-09-20 Genzyme Corp Métodos para tratamento de sintomas neurológicos associados a doenças do armazenamento lisossômic
WO2021214771A1 (en) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
WO2021221953A1 (en) 2020-04-28 2021-11-04 The Regents Of The University Of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
MX2023001014A (es) 2020-07-24 2023-03-01 Genzyme Corp Composiciones farmaceuticas que comprenden venglustat.
CA3187086A1 (en) * 2020-07-30 2022-02-03 Tanya Zaremba FISCHER Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same
BR112023022015A2 (pt) * 2021-05-11 2023-12-26 Green Cross Corp Novos compostos que têm atividade inibidora contra glucosilceramida sintase ou sal farmaceuticamente aceitável da mesma, processos para preparar os mesmos e respectivas composições farmacêuticas
WO2023042177A1 (en) 2021-09-20 2023-03-23 Gt Gain Therapeutics Sa Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide
WO2023239892A1 (en) * 2022-06-10 2023-12-14 Arkuda Therapeutics Compounds for modulation of cd68 and uses thereof
EP4608833A1 (en) * 2022-10-24 2025-09-03 Yuhan Corporation Novel salt of dimethyl-2,3-dihydro-1h-indene derivative and processes for preparing the same
WO2024090919A1 (en) * 2022-10-24 2024-05-02 Yuhan Corporation Improved processes for preparing dimethyl-2,3-dihydro-1h-indene derivatives
WO2024116127A1 (en) 2022-12-01 2024-06-06 Genzyme Corporation Venglustat in combination with a strong or moderate inhibitor of cyp3a4
EP4642455A1 (en) 2022-12-30 2025-11-05 GT Gain Therapeutics SA Method of treating tauopathies
WO2025094117A1 (en) 2023-11-02 2025-05-08 Gt Gain Therapeutics Sa Substituted indolyl compounds, compositions thereof, and therapeutic uses thereof
WO2025159544A1 (en) * 2024-01-26 2025-07-31 Yuhan Corporation Pharmaceutical composition for preventing or treating gaucher disease
WO2025215582A1 (en) 2024-04-11 2025-10-16 Gt Gain Therapeutics Sa Substituted pyrazolopyridine and pyrazolopyrimidine compounds and their use
WO2025219952A1 (en) 2024-04-19 2025-10-23 Genzyme Corporation Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders
WO2025219951A1 (en) 2024-04-19 2025-10-23 Genzyme Corporation Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders
CN118496159B (zh) * 2024-07-18 2024-09-24 广州医科大学附属市八医院 一种化合物在制备具有预防和/或治疗肝纤维化作用的药物中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (enExample) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
EP0286670B1 (en) * 1986-10-03 1990-12-19 Micro Motion Incorporated Density insensitive coriolis mass flow rate meter
IE62231B1 (en) 1987-12-24 1995-01-11 Wyeth John & Brother Ltd Heterocyclic compounds
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
CA2182568A1 (en) * 1994-02-10 1995-08-17 Makoto Takeuchi Novel carbamate derivative and medicinal composition containing the same
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
AU7551896A (en) * 1995-11-08 1997-05-29 American Home Products Corporation 1-azabicycloheptane derivatives and their pharmaceutical use
AU734290B2 (en) 1997-10-29 2001-06-07 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
GB0010955D0 (en) * 2000-05-05 2000-06-28 Novartis Ag Organic compounds
JP4445704B2 (ja) * 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
DE60216830T2 (de) * 2001-02-06 2007-06-14 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
JP2003267977A (ja) * 2002-03-14 2003-09-25 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
JP4575156B2 (ja) * 2002-07-17 2010-11-04 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
AU2003248122A1 (en) * 2002-07-25 2004-02-16 Kotobuki Pharmaceutical Co., Ltd. Sodium channel inhibitor
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
EP1581223B2 (en) * 2002-12-06 2016-05-25 The Feinstein Institute for Medical Research Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
JP2007186422A (ja) * 2004-01-28 2007-07-26 Astellas Pharma Inc アリールスルフィド誘導体
CA2571584A1 (en) * 2004-06-23 2006-01-05 The Feinstein Institute For Medical Research Method of treating ileus by pharmacological activation of cholinergic receptors
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
WO2007100430A2 (en) * 2006-01-27 2007-09-07 Yale University Cytisine and acetylcholine analogs and methods of treating mood disorders
US7840109B2 (en) * 2006-08-14 2010-11-23 Adc Telecommunications, Inc. Factory spliced cable assembly
AU2008334094B2 (en) * 2007-11-29 2015-01-22 Neuraltus Pharmaceuticals, Inc. Compositions and methods for treating lysosomal disorders
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2731685A1 (en) * 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP2323652A2 (en) * 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
EP2154136A1 (en) * 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
WO2010091104A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
WO2010091164A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
US8821599B2 (en) * 2009-06-09 2014-09-02 Sundrop Fuels, Inc. Systems and methods for biomass gasifier reactor and receiver configuration
MX392330B (es) 2009-08-28 2025-03-11 Icahn School Med Mount Sinai Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonado de la dosis para tratar la deficiencia de esfingomielinasa ácida.
TWI634119B (zh) * 2011-03-18 2018-09-01 美商健臻公司 葡萄糖神經醯胺合成酶抑制劑

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI634119B (zh) * 2011-03-18 2018-09-01 美商健臻公司 葡萄糖神經醯胺合成酶抑制劑
TWI865485B (zh) * 2019-02-04 2024-12-11 美商健臻公司 用於治療溶體儲積症相關的症狀和病症之方法（一）

Also Published As

Publication number Publication date
CA2830540C (en) 2021-04-27
SI3673906T1 (sl) 2025-09-30
UA118248C2 (uk) 2018-12-26
CA2830540A1 (en) 2012-09-27
CN103917094B (zh) 2016-11-09
AR085425A1 (es) 2013-10-02
US20160207933A1 (en) 2016-07-21
US20210261557A1 (en) 2021-08-26
US20140371460A1 (en) 2014-12-18
MX2019008428A (es) 2019-10-30
EP3673906B1 (en) 2025-05-14
JP6117708B2 (ja) 2017-04-19
EP2685986A2 (en) 2014-01-22
TW201716404A (zh) 2017-05-16
IL228514B (en) 2019-09-26
CN107080747A (zh) 2017-08-22
MX365245B (es) 2019-05-28
AU2016244305A1 (en) 2016-11-03
NI201300083A (es) 2014-02-28
LT2685986T (lt) 2020-03-10
RU2018104472A (ru) 2019-02-22
WO2012129084A2 (en) 2012-09-27
TWI634119B (zh) 2018-09-01
BR112013023774B1 (pt) 2022-01-11
NZ615857A (en) 2016-08-26
TW201300383A (zh) 2013-01-01
HRP20200226T1 (hr) 2020-05-29
AU2012231275A1 (en) 2013-10-17
HRP20250907T1 (hr) 2025-09-26
GT201300215A (es) 2015-02-09
ECSP13012978A (es) 2015-04-30
EP2685986B1 (en) 2019-11-27
RS67073B1 (sr) 2025-08-29
HUE047888T2 (hu) 2020-05-28
BR122019017719B1 (pt) 2022-08-23
RS59963B1 (sr) 2020-03-31
CR20190034A (es) 2019-05-20
PE20140412A1 (es) 2014-04-01
MY173998A (en) 2020-03-03
ES2774293T3 (es) 2020-07-20
MX2013010710A (es) 2013-10-17
EP4559918A2 (en) 2025-05-28
ZA201307016B (en) 2014-05-28
EP2685986A4 (en) 2015-03-04
CN107080747B (zh) 2021-02-26
CO6801749A2 (es) 2013-11-29
CL2013002688A1 (es) 2014-03-07
RU2645675C2 (ru) 2018-02-27
US20200048266A1 (en) 2020-02-13
US9139580B2 (en) 2015-09-22
PH12013501944A1 (en) 2013-10-14
PT3673906T (pt) 2025-07-29
US20140255381A1 (en) 2014-09-11
CN103917094A (zh) 2014-07-09
PT2685986T (pt) 2020-03-05
US9126993B2 (en) 2015-09-08
KR20140092239A (ko) 2014-07-23
LT3673906T (lt) 2025-08-11
PL2685986T3 (pl) 2020-07-27
MA35023B1 (fr) 2014-04-03
JP2017141255A (ja) 2017-08-17
DK2685986T3 (da) 2020-03-02
BR112013023774A2 (pt) 2016-12-06
PL3673906T3 (pl) 2025-09-22
MX368340B (es) 2019-09-30
ES3037907T3 (en) 2025-10-08
DK3673906T3 (da) 2025-08-18
KR101987736B1 (ko) 2019-06-11
WO2012129084A3 (en) 2014-04-24
AU2016244305B2 (en) 2018-05-24
JP2014517808A (ja) 2014-07-24
SI2685986T1 (sl) 2020-03-31
FI3673906T3 (fi) 2025-08-14
RU2018104472A3 (enExample) 2021-04-30
DOP2013000209A (es) 2014-04-15
IL228514A0 (en) 2013-12-31
EP3673906A1 (en) 2020-07-01
HUE072576T2 (hu) 2025-11-28
UY33958A (es) 2012-10-31
JP6420860B2 (ja) 2018-11-07
RU2013146550A (ru) 2015-04-27
EP4559918A3 (en) 2025-11-19

Similar Documents

Publication Publication Date Title
TWI546301B (zh) 葡萄糖神經醯胺合成酶抑制劑
US12060349B2 (en) Glucosylceramide synthase inhibitors
HK40033123A (en) Glucosylceramide synthase inhibitors
HK40033123B (en) Glucosylceramide synthase inhibitors
NZ615857B2 (en) Glucosylceramide synthase inhibitors
OA16599A (en) Glucosylceramide synthase inhibitors.
SG193532A1 (en) Glucosylceramide synthase inhibitors